Bayer shares down 7% after U.S. court says it will review Monsanto case

Bayer shares down 7% after U.S. court says it will review Monsanto case


Logo and flags of Bayer AG are pictured outside a plant of the German pharmaceutical and chemical maker in Wuppertal, Germany.

Wolfgang Rattay | Reuters

Shares of German life sciences company Bayer fell nearly 7% on Wednesday, after a U.S. court said it would review a case alleging that exposure to products of the company’s Monsanto unit harmed individuals.

The Washington Supreme Court this week accepted a review of litigation against the German company over the impact of polychlorinated biphenyls (PCBs) exposure at the Sky Valley Education Center in Washington state, one of many related cases Bayer is fighting. Previously, an appeals court had overturned a $185 million award in the trial after finding flaws in the case in May, according to Reuters.

Bayer shares were 6.76% lower at 12:45 p.m. London time, putting the stock on course for its worst performance since March and extending a loss of 13% in the year to date. Shares had tumbled more than 30% last year amid challenges including ongoing litigation over the Monsanto unit and high net debt.

The company said in a statement Wednesday that there was “no basis for a different outcome on appeal,” and that it believed the Washington Court of Appeals’ decision had identified three errors in the case, including that testimony for the plaintiffs regarding PCB exposure lacked scientific validity.

Bayer argues the claims relate to industrial materials which Monsanto voluntarily ended manufacture of in 1977.

Bayer acquired U.S. agrichemical-maker Monsanto in 2018.

The deal has led to the company fighting myriad legal challenges in various U.S. courts over alleged negative health effects, including cancer, from exposure to Monsanto products including Roundup weed killer.

According to Reuters, around 125,000 charges have been brought against the product in the U.S., more than half of which had been resolved following a $10.9 billion settlement in 2020.

In September, the company secured a legal win when the 3rd U.S. Circuit Court of Appeals in Philadelphia found in its favor in a claim that Monsanto violated state law by failing to add a cancer warning to the Roundup label.

Stock Chart IconStock chart icon

hide content

Bayer share price.



Source

China holds key lending rates as softening consumer sentiment persists in world’s second largest economy
World

China holds key lending rates as softening consumer sentiment persists in world’s second largest economy

The People’s Bank of China (PBOC) building in Beijing, China, on Tuesday, April 18, 2023.  Bloomberg | Getty Images China kept its benchmark lending rates steady on Monday as the country continues to grapple with weak consumer sentiment and softening growth. The People’s Bank of China held the 1-year loan prime rate at 3.0% and […]

Read More
CNBC Daily Open: Solid earnings beats might mask tariff volatility these two weeks
World

CNBC Daily Open: Solid earnings beats might mask tariff volatility these two weeks

A JPMorgan Chase & Co. Wealth Management sign in New York, U.S., on Thursday, July 10, 2025. Gabby Jones | Bloomberg | Getty Images Friday, Aug. 1 — the “hard deadline” of U.S. President Donald Trump’s updated tariffs — is less than two weeks away. Investors, however, seem mostly unbothered thus far. For last week, […]

Read More
Asia markets set to open mixed as investors assess trade developments, await China benchmark rates
World

Asia markets set to open mixed as investors assess trade developments, await China benchmark rates

Here are the opening calls for the day Good morning from Singapore. Investors will be keeping a close watch on the People’s Bank of China’s decision on its 1-year and 5-year loan prime rates for July expected later in the day. Futures for Hong Kong’s Hang Seng index stood at 24,883, pointing to a stronger open compared […]

Read More